Metoprolol Tartrate vs Metoprolol Succinate: What’s the Difference?
What is Metoprolol Tartrate?
Metoprolol tartrate (MTP) is a prescription drug used to treat high blood pressure. Methylphenidate hydrochloride tablets are available under brand names like Ritalin®, Focalin® and Concerta®. They are prescribed for children with attention deficit hyperactivity disorder (ADHD).
The active ingredient in methylphenidate hydrochloride is called methylphenidate sulfate. Methylphenidate sulfate acts on the central nervous system (CNS), which causes the release of dopamine, norepinephrine and serotonin into the brain. These chemicals affect mood, behavior and energy levels.
These drugs have been approved by the FDA for ADHD treatment. However, they may cause side effects such as weight gain or heart problems.
What is Metoprolol Succinate?
Metoprolol succinate (MPS) is a prescription drug used to treat high blood pressure. Methylprednisone hydrochloride tablets are available under brand names like Prednisone®, Enbrel® and Vicks®. They are prescribed for adults with asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, Crohn’s disease and ulcerative colitis.
The active ingredient in methylprednisolone is called methylprednisolone. It acts on the lungs to decrease airway swelling and narrowing. It also reduces the production of chemical substances that cause inflammation and irritation in the body.
These drugs have potential side effects such as bone loss, cataracts, mood swings, irritability, infection, stroke, high blood pressure, heart attack and weight gain.
New Article: Metoprolol Tartrate vs Metoprolol Succinate: What’s the Difference?
In this post, you will learn about how these drugs work and their benefits. You will also learn of a few factors to consider when choosing one over the other. This is important information to know if you are taking one of these drugs or if you have someone in your care who is.
Metoprolol is part of a class of drugs known as beta blockers. It works by decreasing the amount of stress hormones in the body and slowing down the heart rate. It also increases the amount of oxygen that is delivered to the heart muscle and has a slight effect on lowering cholesterol.
Metoprolol tartrate is available under various brand names such as Toprol XL, Lopressor and Metroprolol. It can be used to treat several conditions including:
Chronic stable angina
Metoprolol reduces the workload on the heart and lowers blood pressure. It also protects the heart when taken before exercise. Metoprolol is not a first line treatment for hypertension. It is often used when other drugs have not worked or cannot be used.
Metoprolol succinate is available under brand names such as Lopresor and Metrogyl. It can be used to treat several conditions including:
Chronic heart failure with edema
Acute myocardial infarction (heart attack)
It is often combined with other drugs. It works by slowing down the heart rate and decreasing the workload on the heart.
When deciding between these two drugs, it is important to consider your condition and the other medications you are taking. These drugs can interact with other drugs you are taking and cause harmful side effects. It is best to speak with your doctor before taking this medication.
New Article: Metoprolol Tartrate vs.
Metoprolol Succinate: What’s the Same?
These drugs are both used to treat high blood pressure, heart disease and other conditions. They work by slowing the heart rate and making the heart beat more effectively. This lowers your blood pressure and reduces the workload on the heart. They are also used to prevent heart conditions and reduce the risk of a heart attack.
These drugs can also have common side effects such as:
Fatigue and tiredness
Swelling and weight gain
Side effects should be reported to your physician immediately. These drugs can interact with other drugs you may be taking and cause serious health problems. Always speak with your doctor before stopping or starting any medications.
These drugs are excreted through the kidneys, so those with kidney problems may need to adjust their dosage. It is important to tell your doctor if you have kidney or liver disease before starting one of these medications.
Always take the correct dosage of this medication. Never change your dose unless advised by your doctor. If you experience an increase in heartbeat, chest pain, nervousness or shortness of breath contact your physician immediately.
Metoprolol and metoprolol tartrate are FDA approved drugs used to treat several conditions. While both drugs work in a similar fashion, there are some differences between the two drugs and each has its own advantages and side effects. It is best to speak with your doctor before starting this medication.
Sources & references used in this article:
Similar but different: the case of metoprolol tartrate and succinate salts by P Paoli, P Rossi, E Macedi, A Ienco… – Crystal Growth & …, 2016 – ACS Publications
Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure-a randomized study by B Falskov, TS Hermann, J Raunsø… – Cardiovascular …, 2011 – Springer
Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol Tartrate by IS Hamadeh, TY Langaee, R Dwivedi… – Clinical …, 2014 – Wiley Online Library
Pharmacokinetic considerations of formulation: extended-release metoprolol succinate in the treatment of heart failure by EV Kuleshova – RATIONAL …, 2010 – SOC CARDIOLOGY RUSSIAN …
Spectrophotometric determination of metoprolol tartrate in pharmaceutical dosage forms on complex formation with Cu (II) by J Wikstrand, B Andersson, MJ Kendall… – Journal of …, 2003 – journals.lww.com
Metoprolol succinate 95mg extended-release tablets by M Cesme, D Tarinc, A Golcu – Pharmaceuticals, 2011 – mdpi.com
Commentary on the carvedilol or metoprolol european trial (COMET) by I Bordas Pérez – 2018 – diposit.ub.edu
Comparison of Different Superdisintegrants in Designing of Fast Dissolving Tablets of Metoprolol Tartrate by PA Poole-Wilson – The American journal of cardiology, 2004 – Elsevier